미세잔존질환 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Minimal Residual Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1878908
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 미세잔존질환(MRD) 검사 시장은 2024년에 14억 5,000만 달러로 평가되었으며, 2030년까지 CAGR 8.70%로 성장하여 23억 9,000만 달러에 달할 것으로 예측됩니다.
미세잔존질환(MRD) 검사는 치료 후 환자의 체내에 남아있는 미량의 암세포를 검출하는 검사로, 기존 방법으로는 검출이 어려운 경우가 많아 질병의 재발을 크게 예측할 수 있습니다. 이러한 세계 시장 확대는 기본적으로 다양한 혈액 악성종양 발생률의 증가와 차세대 시퀀싱 및 고감도 유세포 분석과 같은 진단 기술의 지속적인 발전에 의해 촉진되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
14억 5,000만 달러
시장 규모 : 2030년
23억 9,000만 달러
CAGR : 2025-2030년
8.7%
가장 빠르게 성장하는 부문
차세대 시퀀싱
최대 시장
북미
주요 시장 촉진요인
전 세계적으로 증가하는 암 및 혈액 악성 종양 발생률은 미세잔존질환 검사 시장을 이끄는 주요 요인입니다. 인구 증가와 고령화에 따라 새로운 암 진단 건수는 지속적으로 증가하고 있으며, 치료 과정 및 경과 관찰을 통해 고도의 모니터링 도구를 필요로 하는 환자층이 직접적으로 확대되고 있습니다.
주요 시장 과제
고도의 미세잔존질환 검사 기술에 따른 높은 비용은 시장 확대에 큰 장벽이 되고 있습니다. 이러한 경제적 요인은 특히 예산 제약에 직면한 의료 시스템이나 환자 본인 부담금이 높은 지역에서 환자의 접근을 직접적으로 제한하고 보급을 방해하고 있습니다.
주요 시장 동향
고형 종양에서 미세잔존질환(MRD) 검사의 임상적 유용성 확대는 혈액악성종양에서 이미 확립된 역할을 넘어서는 중요한 시장 동향입니다. 이러한 변화는 보다 광범위한 환자 집단에서 치료 후 보다 정밀한 모니터링과 재발 예측에 대한 명확한 요구로 인해 추진되고 있습니다.
목차
제1장 제품 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
기술별(유세포 분석, 중합효소 연쇄 반응, 차세대 시퀀싱, 기타)
용도별(백혈병, 림프종, 다발성 골수종, 기타)
최종사용자별(병원·전문 클리닉, 학술·연구기관, 임상 검사실, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 미세잔존질환(MRD) 검사 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 미세잔존질환(MRD) 검사 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
ICON plc
F. Hoffmann-La Roche AG
Bio-Rad Laboratories, Inc.
Laboratory Corporation of America Holdings
Natera, Inc.
Cergentis B.V.
OPKO Health, Inc.
Sysmex Corporation
Mission Bio, Inc.
Invivoscribe, Inc.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Minimal Residual Disease (MRD) Testing Market, valued at USD 1.45 Billion in 2024, is projected to experience a CAGR of 8.70% to reach USD 2.39 Billion by 2030. Minimal residual disease (MRD) testing identifies minute quantities of cancer cells remaining in a patient's body post-treatment, often undetectable by conventional methods, which significantly predict disease relapse. This global market's expansion is fundamentally driven by the rising incidence of various hematological malignancies and continuous advancements in diagnostic technologies, such as next-generation sequencing and highly sensitive flow cytometry.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1.45 Billion
Market Size 2030
USD 2.39 Billion
CAGR 2025-2030
8.7%
Fastest Growing Segment
Next Generation Sequencing
Largest Market
North America
Key Market Drivers
The escalating global incidence of cancer and hematological malignancies represents a primary force propelling the minimal residual disease testing market. As the population grows and ages, the number of new cancer diagnoses continues to rise, directly increasing the patient pool requiring sophisticated monitoring tools throughout their treatment journey and follow-up. MRD testing becomes crucial in managing these conditions by offering precise detection of residual disease after therapy, guiding subsequent treatment decisions, and identifying patients at high risk of relapse.
Key Market Challenges
The high cost associated with advanced minimal residual disease testing technologies represents a significant impediment to market expansion. These economic considerations directly limit patient access and hinder widespread adoption, especially in healthcare systems facing budget constraints or where high patient out-of-pocket expenses are prevalent. The advanced methodologies and specialized infrastructure required for these tests contribute to their elevated cost, thereby making them less attainable for a wider patient demographic.
Key Market Trends
The expanding clinical utility of minimal residual disease (MRD) testing in solid tumors represents a significant market trend, moving beyond its established role in hematological malignancies. This shift is driven by the clear need for more precise post-treatment monitoring and recurrence prediction in a broader patient population. According to the American Cancer Society, in 2023, an estimated 1,958,310 new cancer cases were projected to occur in the United States, with solid tumors constituting the vast majority of these diagnoses, highlighting a substantial and underserved patient base for advanced monitoring solutions. This expansion is further underscored by industry developments, such as Illumina Inc. 's announcement in January 2024 of a collaboration with Janssen Research & Development, LLC to develop a novel molecular residual disease assay. This whole-genome sequencing multi-cancer research solution is specifically designed to detect circulating tumor DNA for various solid tumor indications, signaling growing investment and technological application in this area.
Key Market Players
ICON plc
F. Hoffmann-La Roche AG
Bio-Rad Laboratories, Inc.
Laboratory Corporation of America Holdings
Natera, Inc.
Cergentis B.V.
OPKO Health, Inc.
Sysmex Corporation
Mission Bio, Inc.
Invivoscribe, Inc.
Report Scope:
In this report, the Global Minimal Residual Disease (MRD) Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Minimal Residual Disease (MRD) Testing Market, By Technology:
Flow Cytometry
Polymerase Chain Reaction
Next Generation Sequencing
Others
Minimal Residual Disease (MRD) Testing Market, By Application:
Leukemia
Lymphoma
Multiple Myeloma
Others
Minimal Residual Disease (MRD) Testing Market, By End User:
Hospitals & Specialty Clinics
Academic & Research Institutions
Clinical Laboratories
Others
Minimal Residual Disease (MRD) Testing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Minimal Residual Disease (MRD) Testing Market.
Available Customizations:
Global Minimal Residual Disease (MRD) Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Minimal Residual Disease (MRD) Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, Others)
5.2.2. By Application (Leukemia, Lymphoma, Multiple Myeloma, Others)
5.2.3. By End User (Hospitals & Specialty Clinics, Academic & Research Institutions, Clinical Laboratories, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Minimal Residual Disease (MRD) Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Minimal Residual Disease (MRD) Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Minimal Residual Disease (MRD) Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Minimal Residual Disease (MRD) Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. Europe Minimal Residual Disease (MRD) Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Minimal Residual Disease (MRD) Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. France Minimal Residual Disease (MRD) Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom Minimal Residual Disease (MRD) Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy Minimal Residual Disease (MRD) Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Minimal Residual Disease (MRD) Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. Asia Pacific Minimal Residual Disease (MRD) Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Minimal Residual Disease (MRD) Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Minimal Residual Disease (MRD) Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Minimal Residual Disease (MRD) Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Minimal Residual Disease (MRD) Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Minimal Residual Disease (MRD) Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Minimal Residual Disease (MRD) Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. UAE Minimal Residual Disease (MRD) Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. South Africa Minimal Residual Disease (MRD) Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. South America Minimal Residual Disease (MRD) Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Minimal Residual Disease (MRD) Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Colombia Minimal Residual Disease (MRD) Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Argentina Minimal Residual Disease (MRD) Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Minimal Residual Disease (MRD) Testing Market: SWOT Analysis
